Hemophagocytic lymphohistiocytosis is a rare, life threatening immune condition that primarily affects infants and young children, though it can occur at any age. In patients with this disease, immune cells become dangerously overactive, releasing inflammatory molecules that cause the immune system to attack the body’s own organs, including the liver, brain, and bone marrow. Symptoms typically appear within the first months or years of life and may include persistent fever, an enlarged liver or spleen, and a significantly reduced blood cell count. For decades, patients with hemophagocytic lymphohistiocytosis who failed or could not tolerate conventional therapy had no approved treatment options. The FDA has now changed that.
What Hemophagocytic Lymphohistiocytosis Is and How It Develops
Hemophagocytic lymphohistiocytosis can be inherited, in which case it is referred to as primary or familial HLH, or it can arise from non inherited causes. In primary HLH, a genetic defect impairs the normal function of immune cells, leading to a state of uncontrolled immune activation. Rather than targeting foreign invaders, the overactive immune cells begin destroying healthy tissue throughout the body. Without effective intervention, the condition can rapidly become fatal.
Until the approval of Gamifant, treatment relied on conventional HLH therapy regimens that many patients fail to respond to, develop recurrence on, or cannot tolerate due to toxicity. No drug had ever been specifically approved for hemophagocytic lymphohistiocytosis, leaving clinicians and families with extremely limited options when standard approaches were exhausted.
How Gamifant Works in Hemophagocytic Lymphohistiocytosis
Gamifant, known generically as emapalumab and developed by Novimmune SA, is the first drug to receive FDA approval specifically for the treatment of hemophagocytic lymphohistiocytosis. It is approved for pediatric patients from newborn age and above, as well as adult patients, with primary HLH who have refractory, recurrent, or progressive disease on conventional therapy, or who are intolerant of it.
The drug works by targeting and neutralizing interferon gamma, the key inflammatory molecule that drives the immune overactivation characteristic of hemophagocytic lymphohistiocytosis. By blocking this signaling pathway, Gamifant interrupts the destructive inflammatory cascade rather than broadly suppressing the immune system.
Clinical Trial Results Supporting the HLH Approval
The FDA approval was based on a clinical trial enrolling 27 pediatric patients with suspected or confirmed primary hemophagocytic lymphohistiocytosis, all of whom had refractory, recurrent, or progressive disease, or were intolerant of conventional therapy. The median patient age in the trial was one year old. Results showed that 63 percent of patients experienced a meaningful clinical response, and 70 percent were able to proceed to stem cell transplant, the potentially curative treatment for primary HLH.
Common side effects observed in the trial included infections, hypertension, infusion related reactions, low potassium levels, and fever. Patients receiving Gamifant should not receive live vaccines and should be screened for latent tuberculosis prior to treatment. Close monitoring for infections during therapy is recommended.
Regulatory Designations and What They Mean for Rare Disease Research
The FDA granted Gamifant Priority Review and Breakthrough Therapy designation, both of which are intended to accelerate the development and review of treatments for serious conditions where preliminary evidence suggests substantial improvement over available therapy. Gamifant also received Orphan Drug designation, which provides financial incentives and regulatory support for the development of treatments targeting rare diseases affecting small patient populations.
According to Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence, the approval fills a critical unmet medical need and reflects the agency’s commitment to expediting meaningful treatment options for patients with rare conditions.
FOMAT conducts hematology and rare disease clinical trials at sites across the United States. To learn more about active studies, visit FOMAT’s patient studies page.
For the full source, see the original article at R&D Magazine.